Commercial Services and Supplies
Company Overview of Cancer Research UK
Cancer Research UK is a charitable institution that supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The charity also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. The institute also operates an online portal CancerHelp UK that provides patient information. Cancer Research UK was incorporated in 2001 and is based in London, United Kingdom.
407 St. John Street
London, EC1V 4AD
Founded in 2001
Key Executives for Cancer Research UK
Chief Executive Officer and Chairman of the Executive Board
Compensation as of Fiscal Year 2015.
Cancer Research UK Key Developments
BioInvent International Reaches Agreement with Cancer Research UK, and Leukaemia & Lymphoma Research to Take its Investigational Drug
Jan 20 15
BioInvent International reached an agreement with Cancer Research UK, and Leukaemia & Lymphoma Research to take its investigational drug, BI-1206, into a collaborative phase I/II trial for patients with chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL). The first in man study will be funded and conducted by Cancer Research UK, CRT and LLR. BioInvent has been granted the option to take up an exclusive license to the study data, subject to payment of milestones and royalties to Cancer Research Technology. BI-1206 is a fully-human anti-CD32b antagonistic antibody that in addition to directly killing tumour cells is thought to work by maintaining CD20 antibodies on the cell membrane of cancer cells, preventing them from becoming resistant to the current treatment, rituximab. The antibody has shown promise both in combination with CD20 antibodies and as a single agent in chronic lymphocytic lymphoma (CLL) and other types of NHL, in an extensive package of preclinical studies carried out by Leukaemia & Lymphoma Research-funded scientists at the University of Southampton. The potential development opportunity for BI-1206 may extend well beyond NHL. The open label Phase I/ll study will enroll between 50 and 60 patients who will receive either BI-1206 alone or BI-1206 in combination with rituximab. The study will primarily enroll CLL patients but smaller cohorts of patients with other types of NHL, such as mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma, may also be recruited. The study is expected to commence in the second half of 2015. It is the first drug to be entered into a new partnership through which Cancer Research UK and Leukaemia & Lymphoma Research will be jointly funding early phase clinical trials for patients with blood cancers. Cancer Research UK's CDD will manage and sponsor the study through the Experimental Cancer Medicine Centre (ECMC) network, with Leukaemia & Lymphoma Research providing the majority of the funding.
MedImmune Enter into Collaboration with Cancer Research UK and Cancer Research Technology to Jointly Establish Biologic Cancer Medicine Lab
Sep 29 14
MedImmune has entered into a collaboration with Cancer Research UK and its Cancer Research Technology (CRT). The collaboration is intended to jointly establish a laboratory in Cambridge, UK, to focus on the discovery and development of novel biologic cancer treatments over an initial five-year period. Scientists from both organizations will work side-by-side on multiple oncology projects at the new CRUK-MEDI Alliance Laboratory. Cancer Research UK, will provide set-up and operational funding for the laboratory and will contribute a portfolio of novel drug targets together with a team of scientists. MedImmune will oversee the laboratoryactivities and provide access to its human antibody phage display libraries and established antibody-engineering technologies. The joint team will share knowledge and expertise to discover and develop antibodies to treat cancer.
Cancer Research UK, Cancer Research Technology and Asterias Biotherapeutics Inc. Partner to Trial Immunotherapy Vaccine for Lung Cancer
Sep 11 14
CANCER RESEARCH UK and Cancer Research Technology (CRT) have reached an agreement with Asterias Biotherapeutics, Inc. to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. AST-VAC2 represents the tenth treatment to enter Cancer Research UK's Clinical Development Partnerships (CDP) scheme, with six having progressed into the clinic to date. CDP is a joint initiative between Cancer Research UK's Drug Development Office (DDO) and Cancer Research Technology, to develop promising anti-cancer agents which pharmaceutical companies do not have the resources to progress through early phase clinical trials. AST-VAC2 is a non-patient specific (allogeneic) cancer vaccine designed to stimulate patients' immune systems to attack telomerase, a protein that is expressed in over 95% of cancers but is rarely expressed in normal adult cells. The vaccine was developed following successful early phase clinical trials of a similar, patient specific (autologous) Asterias vaccine, called AST-VAC1, which was derived from patients' blood cells and tested in prostate cancer and acute myeloid leukemia. Unlike AST-VAC1, and other autologous (patient specific) vaccines that are developed from a patient's own cells, AST-VAC2 is derived from human embryonic stem cells (hESCs), meaning it can be produced on a large scale and stored ready for use, rather than having to produce a specific version of the drug for each patient. The trial of AST-VAC2 will evaluate the safety and toxicity of the vaccine, feasibility, stimulation of patient immune responses to telomerase and AST-VAC2, and clinical outcome after AST-VAC2 administration in patients with resected early-stage lung cancer and in patients with advanced forms of the disease. Under the agreement, Asterias will complete development of the manufacturing process for AST-VAC2. Cancer Research UK will then produce the vaccine and conduct the phase 1/2 clinical trial in the UK. On completion of the clinical trial, Asterias will have an exclusive first option to acquire a license to the data from the trial on pre-agreed terms including an upfront payment, milestones and royalties on sales of products. If Asterias declines this option, CRT will then have an option to obtain a license to Asterias' intellectual property to continue the development and commercialisation of AST-VAC2 and related products in exchange for a revenue share to Asterias of development and partnering proceeds.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|